DrugPatentWatch Database Preview
NEURACEQ Drug Profile
When do Neuraceq patents expire, and when can generic versions of Neuraceq launch?
Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-three patent family members in twenty-five countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
Summary for NEURACEQ
| International Patents: | 33 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 4 |
| DailyMed Link: | NEURACEQ at DailyMed |
Generic Entry Opportunity Date for NEURACEQ
Generic Entry Date for NEURACEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NEURACEQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| William Charles Kreisl | Phase 1/Phase 2 |
| Ulsan University Hospital | N/A |
| National Institute on Aging (NIA) | Phase 2 |
Pharmacology for NEURACEQ
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
Synonyms for NEURACEQ
| [18F]BAY 94-9172 |
| 18F-BAY94-9172 |
| 18F-Florbetaben |
| 4-((1E)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-N-methylaniline |
| 4-[(E)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline |
| 4-{(E)-2-[4-(2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl}-N-methylaniline |
| 902143-01-5 |
| AV-1 |
| BAY 94-9172 |
| BAY-949172 |
| BAY94-9172 |
| CHEBI:79033 |
| CHEMBL566752 |
| DB09148 |
| DTXSID20238065 |
| Florbetaben |
| florbetaben ((18)F) |
| Florbetaben ((sup 18)F) |
| Florbetaben (18F) |
| Florbetaben (18F) (JAN/INN) |
| Florbetaben (18F) [INN] |
| Florbetaben 18F [INN] |
| Florbetaben F 18 |
| Florbetaben F-18 |
| Florbetaben F18 |
| Florbetaben f18 [USAN] |
| GTPL7769 |
| Neuraceq (TN) |
| SCHEMBL11301755 |
| TLA7312TOI |
| UNII-TLA7312TOI |
US Patents and Regulatory Information for NEURACEQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEURACEQ
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2213652 | Start Trial |
| Eurasian Patent Organization | 012334 | Start Trial |
| Japan | 2008524243 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NEURACEQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213652 | 221 2-2015 | Slovakia | Start Trial | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224 |
| 2213652 | 8/2015 | Austria | Start Trial | PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224 |
| 2213652 | 15C0012 | France | Start Trial | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
